Format

Send to

Choose Destination
J Pediatr Gastroenterol Nutr. 2018 Mar;66(3):425-427. doi: 10.1097/MPG.0000000000001838.

Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection.

Author information

1
Pediatric Hepatology Department, Cairo Faculty of Medicine.
2
Tropical Medicine and Hepatology Department, Alexandria Faculty of Medicine.
3
Gastroenterology and Endemic Medicine Department, Theodore Research Institute, Cairo.
4
Green CRC, Alexandria, Egypt.

Abstract

Recently, sofosbuvir and the fixed-dose combination of sofosbuvir/ledipasvir were approved for the treatment of chronic hepatitis C virus infection in adolescents, criteria being 12 years old and above or weighing at least 35 kg. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic hepatitis C virus and treated with dual sofosbuvir/daclatasvir therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10) (100% [confidence interval 72.25-100%]) achieved sustained vRVR at week 12 post-treatment with good tolerability and no serious adverse events. These data could provide support to our suggested response-tailored protocol of dual therapy with sofosbuvir/daclatasvir in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.

PMID:
29135824
DOI:
10.1097/MPG.0000000000001838
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center